Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

With more diners skipping mains, drinking less and sharing starters because of weight-loss drugs, the traditional ...

Danish pharmaceutical company Novo Nordisk turned the market upside down when it launched Ozempic, a diabetes drug that ended ...

Vikrant Shrotriya, Managing Director of Novo Nordisk India, said that Ozempic is not a 'party drug' but works with diet and ...

Exclusive: Vikrant Shrotriya, Corporate Vice President & Managing Director, Novo Nordisk India, has warned that the 'wonder drug' Ozemic is not a 'party drug'. In a special conversation with Kalli ...